Annual Accounts Payable
$1.15 M
-$1.77 M-60.64%
December 31, 2023
Summary
- As of February 7, 2025, ONCT annual accounts payable is $1.15 million, with the most recent change of -$1.77 million (-60.64%) on December 31, 2023.
- During the last 3 years, ONCT annual accounts payable has risen by +$5000.00 (+0.44%).
- ONCT annual accounts payable is now -64.99% below its all-time high of $3.28 million, reached on December 31, 2018.
Performance
ONCT Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Payable
$1.20 M
-$705.00 K-37.05%
September 30, 2024
Summary
- As of February 7, 2025, ONCT quarterly accounts payable is $1.20 million, with the most recent change of -$705.00 thousand (-37.05%) on September 30, 2024.
- Over the past year, ONCT quarterly accounts payable has dropped by -$264.00 thousand (-18.06%).
- ONCT quarterly accounts payable is now -67.18% below its all-time high of $3.65 million, reached on March 31, 2008.
Performance
ONCT Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Payable Formula
Accounts Payable = Beginning Accounts Payable + Purchases on Credit − Payments to Suppliers
ONCT Accounts Payable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -60.6% | -18.1% |
| 3 y3 years | +0.4% | -39.0% |
| 5 y5 years | -65.0% | -39.0% |
ONCT Accounts Payable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -60.6% | at low | -58.9% | +4.4% |
| 5 y | 5-year | -60.6% | +31.8% | -58.9% | +37.5% |
| alltime | all time | -65.0% | +200.5% | -67.2% | +569.3% |
Oncternal Therapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $1.20 M(-37.0%) |
| Jun 2024 | - | $1.90 M(+30.2%) |
| Mar 2024 | - | $1.46 M(+27.4%) |
| Dec 2023 | $1.15 M(-60.6%) | $1.15 M(-46.2%) |
| Sep 2023 | - | $2.13 M(-4.1%) |
| Jun 2023 | - | $2.22 M(+13.2%) |
| Mar 2023 | - | $1.96 M(-32.7%) |
| Dec 2022 | $2.92 M(+48.9%) | $2.92 M(+18.8%) |
| Sep 2022 | - | $2.46 M(-2.5%) |
| Jun 2022 | - | $2.52 M(+5.2%) |
| Mar 2022 | - | $2.40 M(+22.3%) |
| Dec 2021 | $1.96 M(+71.4%) | $1.96 M(-28.7%) |
| Sep 2021 | - | $2.75 M(+172.2%) |
| Jun 2021 | - | $1.01 M(-46.7%) |
| Mar 2021 | - | $1.89 M(+65.5%) |
| Dec 2020 | $1.14 M(+31.2%) | $1.14 M(+17.0%) |
| Sep 2020 | - | $977.00 K(-33.5%) |
| Jun 2020 | - | $1.47 M(+6.8%) |
| Mar 2020 | - | $1.38 M(+58.0%) |
| Dec 2019 | $871.00 K(-73.4%) | $871.00 K(-29.2%) |
| Sep 2019 | - | $1.23 M(-55.5%) |
| Jun 2019 | - | $2.77 M(+354.0%) |
| Mar 2019 | - | $609.00 K(-81.4%) |
| Dec 2018 | $3.28 M(+25.9%) | $3.28 M(+5.1%) |
| Sep 2018 | - | $3.12 M(+111.9%) |
| Jun 2018 | - | $1.47 M(-15.3%) |
| Mar 2018 | - | $1.74 M(-33.2%) |
| Dec 2017 | $2.60 M(+113.4%) | $2.60 M(+6.2%) |
| Sep 2017 | - | $2.45 M(+306.5%) |
| Jun 2017 | - | $603.00 K(+17.3%) |
| Mar 2017 | - | $514.00 K(-57.9%) |
| Dec 2016 | $1.22 M(+219.4%) | $1.22 M(-0.2%) |
| Sep 2016 | - | $1.22 M(-11.8%) |
| Jun 2016 | - | $1.39 M(+53.6%) |
| Mar 2016 | - | $903.00 K(+136.4%) |
| Dec 2015 | $382.00 K(-25.4%) | $382.00 K(+107.6%) |
| Sep 2015 | - | $184.00 K(-76.9%) |
| Jun 2015 | - | $797.00 K(+82.0%) |
| Mar 2015 | - | $438.00 K(-14.5%) |
| Dec 2014 | $512.00 K | $512.00 K(+186.0%) |
| Sep 2014 | - | $179.00 K(-82.0%) |
| Jun 2014 | - | $992.00 K(+60.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $619.00 K(-23.4%) |
| Dec 2013 | $808.00 K(-52.7%) | $808.00 K(-35.5%) |
| Sep 2013 | - | $1.25 M(-30.2%) |
| Jun 2013 | - | $1.80 M(+63.3%) |
| Mar 2013 | - | $1.10 M(-35.6%) |
| Dec 2012 | $1.71 M(+40.0%) | $1.71 M(+40.6%) |
| Sep 2012 | - | $1.21 M(-17.0%) |
| Jun 2012 | - | $1.46 M(+56.0%) |
| Mar 2012 | - | $937.00 K(-23.1%) |
| Dec 2011 | $1.22 M(+43.8%) | $1.22 M(+47.0%) |
| Sep 2011 | - | $829.00 K(-27.2%) |
| Jun 2011 | - | $1.14 M(+73.1%) |
| Mar 2011 | - | $658.00 K(-22.4%) |
| Dec 2010 | $848.00 K(-33.1%) | $848.00 K(-26.5%) |
| Sep 2010 | - | $1.15 M(+35.5%) |
| Jun 2010 | - | $851.00 K(+3.0%) |
| Mar 2010 | - | $826.00 K(-34.9%) |
| Dec 2009 | $1.27 M(-55.1%) | $1.27 M(+48.1%) |
| Sep 2009 | - | $856.00 K(-42.9%) |
| Jun 2009 | - | $1.50 M(-6.9%) |
| Mar 2009 | - | $1.61 M(-42.9%) |
| Dec 2008 | $2.82 M(+74.8%) | $2.82 M(+112.3%) |
| Sep 2008 | - | $1.33 M(-10.4%) |
| Jun 2008 | - | $1.48 M(-59.4%) |
| Mar 2008 | - | $3.65 M(+126.1%) |
| Dec 2007 | $1.61 M(+20.8%) | $1.61 M(+23.0%) |
| Sep 2007 | - | $1.31 M(-61.0%) |
| Jun 2007 | - | $3.36 M(+92.4%) |
| Mar 2007 | - | $1.75 M(+30.8%) |
| Dec 2006 | $1.34 M(-5.0%) | $1.34 M(-0.6%) |
| Sep 2006 | - | $1.34 M(+35.8%) |
| Jun 2006 | - | $990.00 K(-49.7%) |
| Mar 2006 | - | $1.97 M(+39.8%) |
| Dec 2005 | $1.41 M(+56.3%) | $1.41 M(-28.0%) |
| Sep 2005 | - | $1.96 M(-32.0%) |
| Jun 2005 | - | $2.88 M(+40.3%) |
| Mar 2005 | - | $2.05 M(+127.7%) |
| Dec 2004 | $900.00 K(+95.2%) | $900.00 K(-24.6%) |
| Sep 2004 | - | $1.19 M(+1.3%) |
| Jun 2004 | - | $1.18 M(+7.3%) |
| Mar 2004 | - | $1.10 M(+138.2%) |
| Dec 2003 | $461.00 K(-23.3%) | $461.00 K |
| Dec 2002 | $601.00 K | - |
FAQ
- What is Oncternal Therapeutics annual accounts payable?
- What is the all time high annual accounts payable for Oncternal Therapeutics?
- What is Oncternal Therapeutics annual accounts payable year-on-year change?
- What is Oncternal Therapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Oncternal Therapeutics?
- What is Oncternal Therapeutics quarterly accounts payable year-on-year change?
What is Oncternal Therapeutics annual accounts payable?
The current annual accounts payable of ONCT is $1.15 M
What is the all time high annual accounts payable for Oncternal Therapeutics?
Oncternal Therapeutics all-time high annual accounts payable is $3.28 M
What is Oncternal Therapeutics annual accounts payable year-on-year change?
Over the past year, ONCT annual accounts payable has changed by -$1.77 M (-60.64%)
What is Oncternal Therapeutics quarterly accounts payable?
The current quarterly accounts payable of ONCT is $1.20 M
What is the all time high quarterly accounts payable for Oncternal Therapeutics?
Oncternal Therapeutics all-time high quarterly accounts payable is $3.65 M
What is Oncternal Therapeutics quarterly accounts payable year-on-year change?
Over the past year, ONCT quarterly accounts payable has changed by -$264.00 K (-18.06%)